Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

Athenex (ATNX) delivered earnings and revenue surprises of -26.19% and 11.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates

The stock price of Athenex Inc (NASDAQ: ATNX) fell by over 55% pre-market. This is why it happened.

ATNX Stock Price Fell Over 55% Pre-Market: Why It Happened

Shares of Athenex (NASDAQ:ATNX) decreased 21.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 89.29% year over year to ($0.53), which missed the estimate of ($0.44).

Athenex: Q4 Earnings Insights

The FDA has issued a complete response letter (CRL) for Athenex Inc's (NASDAQ: ATNX) marketing application seeking approval for oral paclitaxel plus encequidar to treat metastatic breast cancer. The CRL indicated concern about an increase in neutropenia-related sequelae observed on the oral paclitaxel arm compared with the IV paclitaxel arm.

Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer

BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2020.

Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update

Athenex (NASDAQ:ATNX) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.

Athenex's Earnings Outlook

ATNX won one approval in December and has a PDUFA on Feb 28.

Athenex: PDUFA This Week, Depressed Price, Likely Opportunity

BUFFALO, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2020 on Monday, March 1, 2021, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 am Eastern Time.

Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021

Athenex Inc (NASDAQ: ATNX) has launched Klisyri (tirbanibulin) in the U.S., led by the Company's partner Almirall. The launch has triggered a milestone payment of up to $65 million.

Athenex Launches Klisyri In US For Actinic Keratosis; Expands Tirbanibulin Distribution Pact For Additional Territories

BUFFALO, N.Y., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that today marks the U.S. launch of Klisyri® (tirbanibulin) in the United States, led by the Company's partner Almirall. Athenex announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp. (Taiwan Exchange: 6446). Athenex received approval from the U.S. Food and Drug Administration (FDA) for Klisyri® for the topical treatment of actinic keratosis of the face or scalp on December 14, 2020.

Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin

BUFFALO, N.Y., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman, Dr. Johnson Lau, has been discharged from the hospital and is doing well recuperating at home. He continues to carry out the full duties and responsibilities of CEO and Chairman of Athenex.

CEO Dr. Johnson Lau Recuperating from COVID at Home

BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and continues to serve as Athenex's CEO. Under the advice of his physician, he will not be able to attend the 39th Annual J.P. Morgan Healthcare Conference. Athenex's senior management team will continue to participate and present at the 39th Annual J.P. Morgan Healthcare Conference at its previously scheduled presentation time, and investor one-on-one meetings.

CEO Dr. Johnson Lau Contracts COVID-19

BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39th annual J. P. Morgan Healthcare Conference. Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development, will present a corporate overview at the conference.

Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference

Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp. Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall in the U.S. during the first quarter of 2021. Klisyri will be manufactured by Athenex, highlighting the vertically integrated capabilities of the company ranging from a preclinical lead to a developed product for market launch.

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

BUFFALO, N.Y., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of updated Phase 3 PFS and OS data demonstrating clinical benefits in efficacy and tolerability of oral paclitaxel versus IVP in patients with metastatic breast cancer (MBC). The findings further support the superiority of increased ORR observed with oral paclitaxel. These data were presented today during a spotlight poster presentation at the 2020 San Antonio Breast Cancer Symposium (SABCS).

Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer

BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and encequidar (“oral paclitaxel”) data will be presented in four separate poster presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) to be held virtually December 8-11. Presentations will include, from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer (MBC), a spotlight poster on progression-free survival (PFS) and overall survival (OS), and posters on neuropathy (CIPN), and management of gastrointestinal (GI) side effects. An additional poster explores oral paclitaxel in the treatment of cutaneous angiosarcoma of the breast.

Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer

Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update

Collegium Pharmaceutical

These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Investing $5,000 in These 2 Biotechs Could Make You Rich

BUFFALO, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will release third quarter 2020 financial results on Thursday, November 5, 2020, before the market opens, and host a conference call and live audio webcast 8:00am Eastern Time to discuss financial results and provide a business update.

Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

BUFFALO, N.Y. and CHICAGO, Oct. 9, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced that Athenex Oncology, a U.S. based...

Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC)

Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S. Athenex’s first T cell therapy product cleared to advance to the first stage of clinical development in the U.S.

Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

The company announced the pricing of a public offering of common stock.

Why Athenex Stock Is Down Today

BUFFALO, N.Y., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $110 million. In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 14, 2020, subject to customary closing conditions.

Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

BUFFALO, N.Y., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market conditions, 10,000,000 shares of its common stock in an underwritten public offering. In addition, Athenex expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

News for Athenex Stock (ATNX)